Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
Acute treatment of hereditary angioedema due to C1 inhibitor deficiency has become available in the last 10 years and has greatly improved patients’ quality of life. Two plasma-derived C1 inhibitors (Berinert and Cinryze), a recombinant C1 inhibitor (Ruconest/Conestat alpha), a kallikrein inhibitor...
Main Author: | Hilary Longhurst |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-03-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00245/full |
Similar Items
-
Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
by: Hilary J. Longhurst, et al.
Published: (2018-08-01) -
Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA)
by: Roman Nowicki, et al.
Published: (2020-09-01) -
Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor
by: Lundy McKibbin, et al.
Published: (2019-11-01) -
Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
by: Werner Aberer, et al.
Published: (2017-07-01) -
Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
by: Teresa Caballero, et al.
Published: (2018-03-01)